Shehzahdi Shebbrin Moonshi
Research Subjects
Shehzahdi Shebbrin Moonshi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hang Thu Ta
School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia
11 shared publications Yuao Wu
School of Environment and Science
6 shared publicationsAndrew C. Bulmer
School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, 4215, Australia
4 shared publications- Nam-Trung Nguyen
Griffith University
3 shared publications Dimple Sajin
School of Environment and Science
2 shared publicationsFahima Akther
Australian Institute for Nanotechnology and Bioengineering
2 shared publications
Latest Publications
- 3 November 2025
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (1) , 250-267
Vascular-Protective Effects of Cerium Oxide Nanoparticles Complexed with Iron Oxide and Methotrexate: Reversing Atherosclerosis in a Murine Model
- 3 November 2025
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (1) , 250-267
Vascular-Protective Effects of Cerium Oxide Nanoparticles Complexed with Iron Oxide and Methotrexate: Reversing Atherosclerosis in a Murine Model
- 29 September 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (40) , 19658-19667
Preparation Of Protein-Encapsulated Nanoparticles Using Polysuccinimide-Oleylamine For Sustained Protein Release
- 29 September 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (40) , 19658-19667
Preparation Of Protein-Encapsulated Nanoparticles Using Polysuccinimide-Oleylamine For Sustained Protein Release
- 13 August 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (9) , 5330-5342
Multi-organ-on-a-Chip: The Gut and Inflammatory Diseases
Alteration of the human gut is frequently linked to various diseases. While animal models are valuable tools for studying the interactions between hosts and microbes, there is still a need for a physiologically relevant in vitro gut model. This study presents the development of an integrated microfluidic platform that simultaneously incorporates features of both the gut and vascular systems. The gut chamber incorporates cellular layers resembling epithelial cells, while the vascular channel mimics blood vessel endothelial cells and incorporates shear stress forces relevant to blood flow. This multiorgan model provides a more accurate, in vitro representation of human physiological processes and offers new opportunities for studying gut-heart interactions and the impact of inflammatory diseases. The platform's versatility and scalability make it a promising tool for high-throughput screening, disease modeling, and precision medicine applications.
- 13 August 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (9) , 5330-5342
Multi-organ-on-a-Chip: The Gut and Inflammatory Diseases
Alteration of the human gut is frequently linked to various diseases. While animal models are valuable tools for studying the interactions between hosts and microbes, there is still a need for a physiologically relevant in vitro gut model. This study presents the development of an integrated microfluidic platform that simultaneously incorporates features of both the gut and vascular systems. The gut chamber incorporates cellular layers resembling epithelial cells, while the vascular channel mimics blood vessel endothelial cells and incorporates shear stress forces relevant to blood flow. This multiorgan model provides a more accurate, in vitro representation of human physiological processes and offers new opportunities for studying gut-heart interactions and the impact of inflammatory diseases. The platform's versatility and scalability make it a promising tool for high-throughput screening, disease modeling, and precision medicine applications.
- 12 May 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (6) , 4416-4431
Advancements in Using Polymeric Nanoparticles for Blood–Brain Barrier Penetration in Neurological Disorders
Neurological disorders and glioblastoma represent a significant global health burden, affecting billions of individuals and contributing to high rates of morbidity and mortality. A primary obstacle in treating these conditions is the presence of the blood-brain barrier (BBB), a protective barrier that restricts the entry of most therapeutic agents into the brain. Despite this challenge, advancements in nanotechnology, specifically the development of polymeric nanoparticles, offer promising solutions for overcoming the BBB. Key strategies include surface modifications like PEGylation to enhance circulation time, receptor-mediated targeting for specific brain cells, and stimuli-responsive nanoparticles that release drugs in response to pH or reactive oxygen species. Ultrasound-guided delivery, intranasal administration, and magnetic nanoparticle guidance further enhance targeted delivery, while multifunctional nanoparticles enable combination therapies. These nanoparticles, with their customizable properties, allow for targeted and sustained delivery of drugs to the central nervous system, providing new hope in the treatment of both neurodegenerative diseases and brain cancers. In this review, we explore recent strategies that exploit polymeric nanoparticles to improve drug delivery across the BBB, highlighting their potential in revolutionizing therapeutic approaches for neurological disorders.
- 12 May 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (6) , 4416-4431
Advancements in Using Polymeric Nanoparticles for Blood–Brain Barrier Penetration in Neurological Disorders
Neurological disorders and glioblastoma represent a significant global health burden, affecting billions of individuals and contributing to high rates of morbidity and mortality. A primary obstacle in treating these conditions is the presence of the blood-brain barrier (BBB), a protective barrier that restricts the entry of most therapeutic agents into the brain. Despite this challenge, advancements in nanotechnology, specifically the development of polymeric nanoparticles, offer promising solutions for overcoming the BBB. Key strategies include surface modifications like PEGylation to enhance circulation time, receptor-mediated targeting for specific brain cells, and stimuli-responsive nanoparticles that release drugs in response to pH or reactive oxygen species. Ultrasound-guided delivery, intranasal administration, and magnetic nanoparticle guidance further enhance targeted delivery, while multifunctional nanoparticles enable combination therapies. These nanoparticles, with their customizable properties, allow for targeted and sustained delivery of drugs to the central nervous system, providing new hope in the treatment of both neurodegenerative diseases and brain cancers. In this review, we explore recent strategies that exploit polymeric nanoparticles to improve drug delivery across the BBB, highlighting their potential in revolutionizing therapeutic approaches for neurological disorders.
- Open Access
- 5 December 2024
- Published by Elsevier in Materials Today Bio
- Vol. 30, 101377
A methotrexate labelled dual metal oxide nanocomposite for long-lasting anti-cancer theranostics
- 5 December 2024
- Published by Elsevier in Materials Today Bio
- Vol. 30, 101377
Open AccessA methotrexate labelled dual metal oxide nanocomposite for long-lasting anti-cancer theranostics
- Open Access
- 11 March 2024
- Published by Elsevier in Applied Materials Today
- Vol. 37
Polysuccinimide-based nanoparticle: A nanocarrier with drug release delay and zero burst release properties for effective theranostics of cancer
- 11 March 2024
- Published by Elsevier in Applied Materials Today
- Vol. 37
Open AccessPolysuccinimide-based nanoparticle: A nanocarrier with drug release delay and zero burst release properties for effective theranostics of cancer
- Open Access
- 15 November 2023
- Published by IOP Publishing in Nanotechnology
- Vol. 35 (5) , 055101
Preparation of protein-loaded nanoparticles based on poly(succinimide)-oleylamine for sustained protein release: a two-step nanoprecipitation method
Currently, the treatment for acute disease encompasses the use of various biological drugs (BDs). However, the utilisation of BDs is limited due to their rapid clearance and non-specific accumulation in unwanted sites, resulting in a lack of therapeutic efficacy together with adverse effects. While nanoparticles are considered good candidates to resolve this problem, some available polymeric carriers for BDs were mainly designed for long-term sustained release. Thus, there is a need to explore new polymeric carriers for the acute disease phase that requires sustained release of BDs over a short period, for example for thrombolysis and infection. Poly(succinimide)-oleylamine (PSI-OA), a biocompatible polymer with a tuneable dissolution profile, represents a promising strategy for loading BDs for sustained release within a 48-h period. In this work, we developed a two-step nanoprecipitation method to load the model protein (e.g. bovine serum albumin and lipase) on PSI-OA. The characteristics of the nanoparticles were assessed based on various loading parameters, such as concentration, stirring rate, flow rate, volume ratio, dissolution and release of the protein. The optimised NPs displayed a size within 200 nm that is suitable for vasculature delivery to the target sites. These findings suggest that PSI-OA can be employed as a carrier for BDs for applications that require sustained release over a short period.
- 15 November 2023
- Published by IOP Publishing in Nanotechnology
- Vol. 35 (5) , 055101
Open AccessPreparation of protein-loaded nanoparticles based on poly(succinimide)-oleylamine for sustained protein release: a two-step nanoprecipitation method
Currently, the treatment for acute disease encompasses the use of various biological drugs (BDs). However, the utilisation of BDs is limited due to their rapid clearance and non-specific accumulation in unwanted sites, resulting in a lack of therapeutic efficacy together with adverse effects. While nanoparticles are considered good candidates to resolve this problem, some available polymeric carriers for BDs were mainly designed for long-term sustained release. Thus, there is a need to explore new polymeric carriers for the acute disease phase that requires sustained release of BDs over a short period, for example for thrombolysis and infection. Poly(succinimide)-oleylamine (PSI-OA), a biocompatible polymer with a tuneable dissolution profile, represents a promising strategy for loading BDs for sustained release within a 48-h period. In this work, we developed a two-step nanoprecipitation method to load the model protein (e.g. bovine serum albumin and lipase) on PSI-OA. The characteristics of the nanoparticles were assessed based on various loading parameters, such as concentration, stirring rate, flow rate, volume ratio, dissolution and release of the protein. The optimised NPs displayed a size within 200 nm that is suitable for vasculature delivery to the target sites. These findings suggest that PSI-OA can be employed as a carrier for BDs for applications that require sustained release over a short period.
- 31 August 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (19) , 18775-18791
A Bioactive Disintegrable Polymer Nanoparticle for Synergistic Vascular Anticalcification
Although poly(aspartic acid) (PASP), a strong calcium chelating agent, may be potentially effective in inhibition of vascular calcification, its direct administration may lead to side effects. In this study, we employed polysuccinimide, a precursor of PASP, to prepare targeted polysuccinimide-based nanoparticles (PSI NPs) that not only acted as a prodrug but also functioned as a carrier of additional therapeutics to provide powerful synergistic vascular anticalcification effect. This paper shows that chemically modified PSI-NPs can serve as effective nanocarriers for loading of hydrophobic drugs, in addition to anticalcification and antireactive oxygen species (anti-ROS) activities. Curcumin (Cur), with high loading efficiency, was encapsulated into the NPs. The NPs were stable for 16 h in physiological conditions and then slowly dissolved/hydrolyzed to release the therapeutic PASP and the encapsulated drug. The drug release profile was found to be in good agreement with the NP dissolution profile such that complete release occurred after 48 h at physiological conditions. However, under acidic conditions, the NPs were stable, and Cur cumulative release reached only 30% after 1 week. Though highly effective in the prevention of calcium deposition, PSI NPs could not prevent the osteogenic trans-differentiation of vascular smooth muscle cells (VSMCs). The presence of Cur addressed this problem. It not only further reduced ROS level in macrophages but also prevented osteogenic differentiation of VSMCs in vitro. The NPs were examined in vivo in a rat model of vascular calcification induced by kidney failure through an adenine diet. The inclusion of Cur and PSI NPs combined the therapeutic effects of both. Cur-loaded NPs significantly reduced calcium deposition in the aorta without adversely affecting bone integrity or noticeable side effects/toxicity as examined by organ histological and serum biochemistry analyses.
- 31 August 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (19) , 18775-18791
A Bioactive Disintegrable Polymer Nanoparticle for Synergistic Vascular Anticalcification
Although poly(aspartic acid) (PASP), a strong calcium chelating agent, may be potentially effective in inhibition of vascular calcification, its direct administration may lead to side effects. In this study, we employed polysuccinimide, a precursor of PASP, to prepare targeted polysuccinimide-based nanoparticles (PSI NPs) that not only acted as a prodrug but also functioned as a carrier of additional therapeutics to provide powerful synergistic vascular anticalcification effect. This paper shows that chemically modified PSI-NPs can serve as effective nanocarriers for loading of hydrophobic drugs, in addition to anticalcification and antireactive oxygen species (anti-ROS) activities. Curcumin (Cur), with high loading efficiency, was encapsulated into the NPs. The NPs were stable for 16 h in physiological conditions and then slowly dissolved/hydrolyzed to release the therapeutic PASP and the encapsulated drug. The drug release profile was found to be in good agreement with the NP dissolution profile such that complete release occurred after 48 h at physiological conditions. However, under acidic conditions, the NPs were stable, and Cur cumulative release reached only 30% after 1 week. Though highly effective in the prevention of calcium deposition, PSI NPs could not prevent the osteogenic trans-differentiation of vascular smooth muscle cells (VSMCs). The presence of Cur addressed this problem. It not only further reduced ROS level in macrophages but also prevented osteogenic differentiation of VSMCs in vitro. The NPs were examined in vivo in a rat model of vascular calcification induced by kidney failure through an adenine diet. The inclusion of Cur and PSI NPs combined the therapeutic effects of both. Cur-loaded NPs significantly reduced calcium deposition in the aorta without adversely affecting bone integrity or noticeable side effects/toxicity as examined by organ histological and serum biochemistry analyses.
- 21 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (36) , 42153-42169
Spiky Silver–Iron Oxide Nanohybrid for Effective Dual-Imaging and Synergistic Thermo-Chemotherapy
Nanophotothermal therapy based on nanoparticles (NPs) that convert near-infrared (NIR) light to generate heat to selectively kill cancer cells has attracted immense interest due to its high efficacy and being free of ionizing radiation damage. Here, for the first time, we have designed a novel nanohybrid, silver-iron oxide NP (AgIONP), which was successfully tuned for strong absorbance at NIR wavelengths to be effective in photothermal treatment and dual-imaging strategy using MRI and photoacoustic imaging (PAI) in a cancer model in vivo and in vitro, respectively. We strategically combine the inherent anticancer activity of silver and photothermal therapy to render excellent therapeutic capability of AgIONPs. In vitro phantoms and in vivo imaging studies displayed preferential uptake of folate-targeted NPs in a cancer mice model, indicating the selective targeting efficiency of NPs. Importantly, a single intravenous injection of NPs in a cancer mice model resulted in significant tumor reduction, and photothermal laser resulted in a further substantial synergistic decrease in tumor size. Additionally, biosafety and biochemical assessment performed in mice displayed no significant difference between NP treatment and control groups. Overall, our folic acid AgIONPs displayed excellent potential in the simultaneous application for safe and successful targeted synergistic photothermal treatment and imaging of a cancer model.
- 21 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (36) , 42153-42169
Spiky Silver–Iron Oxide Nanohybrid for Effective Dual-Imaging and Synergistic Thermo-Chemotherapy
Nanophotothermal therapy based on nanoparticles (NPs) that convert near-infrared (NIR) light to generate heat to selectively kill cancer cells has attracted immense interest due to its high efficacy and being free of ionizing radiation damage. Here, for the first time, we have designed a novel nanohybrid, silver-iron oxide NP (AgIONP), which was successfully tuned for strong absorbance at NIR wavelengths to be effective in photothermal treatment and dual-imaging strategy using MRI and photoacoustic imaging (PAI) in a cancer model in vivo and in vitro, respectively. We strategically combine the inherent anticancer activity of silver and photothermal therapy to render excellent therapeutic capability of AgIONPs. In vitro phantoms and in vivo imaging studies displayed preferential uptake of folate-targeted NPs in a cancer mice model, indicating the selective targeting efficiency of NPs. Importantly, a single intravenous injection of NPs in a cancer mice model resulted in significant tumor reduction, and photothermal laser resulted in a further substantial synergistic decrease in tumor size. Additionally, biosafety and biochemical assessment performed in mice displayed no significant difference between NP treatment and control groups. Overall, our folic acid AgIONPs displayed excellent potential in the simultaneous application for safe and successful targeted synergistic photothermal treatment and imaging of a cancer model.
- Open Access
- 9 February 2023
- Published by Elsevier in Applied Materials Today
- Vol. 31
Gold-iron oxide nanoparticle: A unique multimodal theranostic approach for thrombosis
- 9 February 2023
- Published by Elsevier in Applied Materials Today
- Vol. 31
Open AccessGold-iron oxide nanoparticle: A unique multimodal theranostic approach for thrombosis